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In vivo administration f the phenothiazine drug, thioridazine, inhibits hepatic peroxisomal fl-oxidation in 
mice. In starving animals, 3-hydroxybutyrate concentration is not decreased by thioridazine treatment. 
These results provide the first demonstration f thioridazine as a selective inhibitor of peroxisomal /I-oxida- 
tion in intact animals. Thioridazine might supply a tool for simulation of pathological conditions in which 
peroxisomal #&oxidation is impaired. 
Peroxisome ~-Oxidation Catalase In vivo inkibit~on 
1. INTRODUCTION 
Fatty acid oxidation in liver occurs in 2 different 
cell compartments, mitochondria and peroxisomes 
[ 1,2]. The relative contribution to overall fatty acid 
degradation in the cell and the precise function of 
peroxisomal &oxidation are not clearly established 
[3-71. To gain more insight into peroxisomal func- 
tion, specific inhibitors of peroxisomalfl-oxidation 
would be of great value, especially when they can 
be used in vivo. Though attention has been paid to 
inhibitors of the mitochondrial system, there was 
no description of inhibitors of the peroxisomal 
system until recently. In 1984, Leighton et al. [8] 
demonstrated the selective inhibition of perox- 
isomal &oxidation by 3 phenothiazine drugs, of 
which thioridazine proved to be the most effective. 
These results were obtained with an in vitro system 
(isolated rat hepatocytes). As points of divergence 
between in vitro and in vivo findings are often ap- 
parent [6], the purpose of this study is to in- 
vestigate whether and how specifically thioridazine 
inhibits peroxisomal @oxidation of endogenous 
substrates in intact animals. Due to the fact that 
Abbreviations: aminotriazole, 3-amino-IJ,Ctriazole; 
RCA, residual catalase activity; Th, thioridazine 
Hz02 is produced during the first step of perox- 
isomal &oxidation, changes in Hz02 generation 
can be used to estimate peroxisomal activity. In 
vivo )I202 production in the liver of unanaesthe- 
tized mice can be evaluated by measuring the 
catalase activity which remains after inhibition of 
the catalase-Hz02 complex by 3-amino-1,2,4- 
triazole in combination with methanol [9]. In an 
earlier study we demonstrated that starvation 
causes an increased flux of fatty acids through the 
peroxisomal fatty acid oxidase [9]. We now report 
on the influence of thioridazine on enhanced 
peroxisomal &oxidation in starving mice. 
3-Hydroxybutyrate concentration in serum is used 
as a reflection of mitochondrial activity 
[3,4,10,11]. 
2. MATERIALS AND METHODS 
Male BALB/C mice (20-25 g) were used in our 
experiments. 3-Amino-1,2,4-triazole (1 g/kg in 
0.9% NaCl), methanol (3.2 mmol/kg) and 
thioridazine (in 0.9% NaCl) were administered by 
intraperitoneal injection. Aminotriazole and 
methanol were administered simult~eously. Mice 
were killed by dislocation of the neck 1 h after ad- 
ministration of aminotriazole-methanol and 2 h 
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received standard laboratory diet (A03-UAR, 
France). Starved mice were deprived of food 
(water ad libitum) for 24 h. 
Catalase activity was assayed at 0°C in total liver 
homogenate by the titanium oxysulphate method 
[12]. 1 UB is the amount of catalase which breaks 
down 90% substrate (1.5 mmol HzOz/l) in a 50 ml 
volume at 0°C in 1 min; maximal reaction time is 
10 min. For each animal the catalase activity 
calculated is the mean of 10 measurements after 
l-10 min reaction time. Residual catalase activity 
(RCA) is the catalase activity that remains after in- 
hibition by aminotriazole in combination with 
methanol. A lower RCA reflects a higher Hz02 
production [9]. 
3-Hydroxybutyrate in serum was determined ac- 
cording to Williamson et al. [13]. 
Each experimental group consisted of at least 5 
animals. All results are expressed as the mean f 
SE. For statistical analysis, the Mann-Whitney test 
was used [14]. 
Thioridazine hydrochloride (Th) was a gift from 
Sandoz Pharmaceuticals; aminotriazole was ob- 
tained from Sigma. 
3. RESULTS 
Catalase activity in the liver of untreated, stan- 
dard diet fed mice is 88.68 + 2.48 Uu/g liver [9]. 
Sole administration of Th (250,umoVkg) has no 
influence on this value. 
The influence of Th administration on liver 
RCA is summarized in table 1. 
Enhanced Hz02 production caused by starvation 
is completely undone by treatment with 
50 pmol/kg Th; in fact the level of Hz02 produc- 
tion is reduced to a level seen in fed mice treated 
with Th. At low doses (0.5 and 5 pmol/kg) Th has 
no inhibitory effect on increased liver Hz02 pro- 
duction; the inhibitory effect is less pronounced at 
250 and 5OOrmol/kg of the drug. 
In 24 h starved mice 3-hydroxybutyrate concen- 
tration in serum has risen significantly compared 
to fed animals. Treatment with different doses of 
Th does not decrease 3-hydroxybutyrate concen- 
tration in serum. 
In fed mice also administration of 50 and 
250 ,umol/kg Th significantly increases RCA (P < 
0.05). 
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Table 1 
Influence of thioridazine (Th) treatment on RCA values 
in total mouse liver homogenate and on serum 
3-hydroxybutyrate concentration 
Conditions 
(Th in pmol/kg) 
Fed 
no Th 
Th 50 
The 250 
RCA 3-Hydroxy- 
(Un/g liver) butyrate (mM) 
50.78 + 3.03 (a) 0.33 + 0.03 
72.83 + 1.90 (b) 0.42 + 0.03 
68.89 f 5.70 (c) 0.49 + 0.02 
Starvation, 24 h 
no Th 18.85 f 1.63 (d) 1.06 2 0.04 
Th 0.5 19.68 f 3.11 (e) 1.17 * 0.13 
Th 5.0 27.07 * 2.31 (f) 1.37 + 0.25 
Th 50 61.08 + 5.25 (g) 1.28 + 0.31 
Th 250 49.17 + 3.97 (h) 1.98 + 0.11 
Th 500 39.66 f 5.44 (i) 1.84 * 0.24 
Statistical significance of differences. P < 0.01: a vs d, 
e and f; b and c vs d, e, f and i; all fed 3-hydroxybutyrate 
values vs fasted values. P < 0.05: a vs b, c and i; b and 
c vs h 
4. DISCUSSION 
The present results demonstrate that Th inhibits 
peroxisomal &oxidation in vivo: enhanced flux of 
fatty acids through the peroxisomal oxidase is 
reversed by’treatment with Th. Inhibition is con- 
centration dependent. 
When Th is administered to fed mice we also 
note a significant increase of liver RCA compared 
to fed, untreated animals. This means that there is 
a measurable basal peroxisomal &oxidation pre- 
sent in fed mice. Administration of 50 pmol/kg Th 
to fasting mice inhibits both the basal peroxisomal 
&oxidation and increased peroxisomal P-oxidation 
due to starvation. 
In mouse serum 3-hydroxybutyrate concentra- 
tion is not diminished after treatment with Th in a 
wide range of concentrations. In the living animal 
therefore Th is not inhibiting mitochondrial activi- 
ty, but is selective for peroxisomes. Moreover this 
result proves that the contribution of peroxisomal 
P-oxidation to the production of ketone bodies is 
negligible. 
The level of RCA reached after Th treatment is 
the same in fed and in fasted animals and equal to 
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the level reached after insulin administration to 
fasted mice [9]. This suggests that Hz02 produc- 
tion from &oxidation has reached its minimum, 
and consequently that near therapeutic doses Th 
inhibits peroxisomal &oxidation completely. This 
makes the drug, which can be administered orally, 
an interesting tool for the study of pathological 
conditions in which impairment of peroxisomal 
function related to fatty acid metabolism is 
suspected or proven, such as in adrenoleucodys- 
trophy [ 151, in Zellweger syndrome [ 161 and in 
Refsum’s disease [ 171. Long term administration 
of Th should demonstrate to which extent inhibi- 
tion of peroxisomal &oxidation causes the 
development of a disease. 
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